We have previously demonstrated the potent antitumor capacity of IL-12+IL-18 cDNA (at higher doses) (27) or IL-12 cDNA systemic expression (25, 28) in B16 and other murine tumor models in vivo (3LL and EL4). This evidence concerns the gene IL18 and neoplasm.